Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01436266
Other study ID # H-30452
Secondary ID
Status Terminated
Phase Phase 3
First received September 15, 2011
Last updated March 18, 2014
Start date July 2011
Est. completion date August 2012

Study information

Verified date March 2014
Source Boston University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Misoprostol is a medication used extensively in obstetrics and gynecology for its ability to aid in softening the cervix as well as decreasing blood loss after abortion or vaginal delivery. Opinions vary as to its usefulness in aiding in cervical dilation, and in decreasing blood loss. The investigators propose to conduct a randomized, placebo-controlled trial to evaluate whether misoprostol given buccally 2 hours prior to second trimester surgical abortion decreases blood loss from the procedure. The investigators will also assess whether misoprostol improves cervical dilation, changes the length of the procedure, changes the need for additional mechanical dilation, changes the subjective ease of the procedure, and changes a woman's pain.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date August 2012
Est. primary completion date August 2012
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- English or Spanish speaking

- Gestational age between 16 weeks 6 days and 20 weeks 6 days gestation by ultrasound dating on the day of enrollment

- Ultrasound used for dating purposes must be within the last two weeks.

- Women 18-50 years of age undergoing surgical termination of pregnancy

Exclusion Criteria:

- Spontaneous fetal demise

- Ruptured membranes or intrauterine infection

- Fibroids that significantly distort the uterine shape

- Uterine abnormality such as unicornuate uterus

- Prior transmural myomectomy

- Severe oligohydramnios

- Morbid obesity with BMI>45

- Inability to place osmotic dilators

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Misoprostol
200 mcg buccally prior to procedure
Folic acid
2mg buccally 2 hours prior to procedure

Locations

Country Name City State
United States Boston University Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Boston University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Blood loss Measured blood loss Subjects will be followed for the duration of their procedure visit, lasting one day. Yes
Secondary Cervical dilation Subjects will be followed for the duration of their procedure visit, lasting one day. Yes
Secondary Length of the procedure Subjects will be followed for the duration of their procedure visit, lasting one day. No
Secondary Need for additional mechanical dilation Subjects will be followed for the duration of their procedure visit, lasting one day. Yes
Secondary Subjective provider ease of procedure Subjects will be followed for the duration of their procedure visit, lasting one day. No
Secondary Subject pain before the procedure Subjects will be followed for the duration of their procedure visit, lasting one day. No
Secondary Subject pain during the procedure Subjects will be followed for the duration of their procedure visit, lasting one day. No
See also
  Status Clinical Trial Phase
Completed NCT04588350 - Clinical Investigation Evaluating a New Autotransfusion Device in Cardiac Surgery N/A
Completed NCT05426564 - Exploratory Assessment of the Quantra® System in Adult ECMO Patients
Active, not recruiting NCT05492214 - The Effect of Time Window for Umbilical Cord Clamping During Cesareans on Offspring Hemoglobin and Maternal Blood Loss N/A
Withdrawn NCT05518279 - Early Administration Of Tranexamic Acid And Acute Blood Loss In Patients With Hip Fractures Phase 3
Enrolling by invitation NCT02910115 - Cooling the Uterus in C-section After Dysfunctional Labor N/A
Completed NCT02569658 - Investigation of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty N/A
Completed NCT01048658 - Sevoflurane as an Anesthetic During Dilation and Evacuation Procedures Phase 4
Terminated NCT02908516 - Safety and Efficacy of Oral TXA in Reducing Blood Loss and Transfusion in Hip Fractures Phase 4
Completed NCT04089865 - Oral Versus Intravenous Tranexamic Acid Phase 4
Recruiting NCT06403163 - Transfusion Surveillance in Anaesthesia
Recruiting NCT02265562 - Rectal Misoprostol and Blood Loss During Abdominal Hysterectomy Phase 3
Completed NCT02312440 - Comparison of Topical and Intravenous Tranexamic Acid in Total Hip Arthroplasty Phase 3
Completed NCT02083809 - Effects of Oxytocin on Bleeding Outcomes During Dilation and Evacuation N/A
Completed NCT01895101 - The Effect on Blood Loss of Topical and Intravenous Tranexamic Acid in Cardiac Surgery Patients Phase 4
Completed NCT01099475 - Effect of Intermittent Pedicle Clamping on Hepatocellular Injury During Liver Surgery N/A
Completed NCT00990288 - The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery Phase 4
Completed NCT03365999 - Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement. Phase 2
Recruiting NCT05550623 - Pneumatic Tourniquet Versus no Tourniquet in Transfemoral Amputation N/A
Completed NCT05012202 - Validating a New Point-of-care Device for Estimation of Blood Count in Pregnant Women
Completed NCT02311309 - Epidemiology of Severe Peroperative Bleeding During Scheduled Surgery N/A